Targeting Galectin-9 to reduce HIV persistence
Official title: Modulation of Galectin-9 to Target HIV Persistence
Funded at Vitalant · NIH-11022900 · Data updated 2026-11-12
This study is looking at how a protein called Galectin-9 might help HIV hide in the body even when people are on treatment, and it hopes to find new ways to get rid of the virus for good, so patients with HIV can have healthier immune systems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vitalant NIH-funded |
| Lab location | 1 site (Scottsdale, United States) |
| Project start | August 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $775,391 |
| NIH project number | 1R01AI184421-01A1 |
| Project ID | NIH-11022900 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who are currently on antiretroviral therapy but still have detectable levels of HIV in their system.
✕Less likely to help
Patients who are not living with HIV or those who have achieved complete viral suppression without any latent infection may not benefit from this research.
What this research studies
This research investigates the role of Galectin-9 in the persistence of HIV in patients undergoing antiretroviral therapy. It aims to understand how Galectin-9 affects immune responses and contributes to the maintenance of latent HIV in CD4+ T cells. By exploring the potential of inhibiting Galectin-9 signaling, the study seeks to develop new strategies for eradicating or functionally curing HIV infection. Patients may be involved in trials assessing the effects of this modulation on HIV persistence and immune health.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that help eliminate HIV from the body or improve immune function in HIV-infected individuals.
How similar studies have gone: Previous research has shown promising results in targeting immune modulators like Galectin-9 for HIV treatment, indicating potential for success in this approach.
Where this research is happening
-
Vitalant
Scottsdale, United States Active
Researchers
- Principal investigator: Pillai, Satish Kumar — Vitalant
- Study coordinator: Pillai, Satish Kumar
Related research
Other NIH-funded projects on the same topics.
-
Using Stored Platelets to Improve Bleeding Control
This project tests how storing platelets at cold temperatures, with possible nutrient tweaks, can boost their ability to stop bleeding in patients who are actively bleeding.
-
Nationwide blood donor study to track respiratory viruses and immune responses
This project uses a large national blood donor network to monitor how common respiratory viruses are and what antibodies people have, helping us understand how past infections and immunity change over time.
-
Modulating Galectin-9 to help reduce HIV persistence
Researchers are exploring whether blocking Galectin-9 can help reduce hidden HIV reservoirs in people on therapy.
-
Extracellular Vesicles as Clues and Targets for Heart Disease in People with HIV
This grant investigates how tiny particles in the blood, called extracellular vesicles, relate to heart disease risk in people living with HIV and looks for new ways to prevent or treat it.
-
How tiny DNA fragments in the blood may help the immune system control HIV
This project explores whether tiny fragments of DNA in the blood trigger immune signals that help delay HIV coming back in people on HIV treatment.
-
Blood and immune cell development in the chorion during early pregnancy
This research looks at how blood-forming stem cells and immune cells in the chorion (a fetal membrane) develop during the first trimester to understand how the placenta helps protect the baby.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.